THE Johnson & Johnson said on Tuesday, 21, that an additional dose of his vaccine against covid-19, applied two months after the initial dose, increased protection against the disease in participants in a clinical trial.
In a statement, J&J said the results of a phase 3 study with volunteers from 10 countries – including the US – who received a second dose two months after the first had 75% protection against symptomatic covid-19. In the US alone, the rate of protection against the disease was 94%. The company did not explain the reason for the difference between the effectiveness rates.
J&J also said the second dose guaranteed volunteers 100% protection against more severe versions of covid-19 for at least two weeks after immunization.
“We now generate evidence that an additional dose increases protection against covid-19 and should significantly extend the term of protection,” said Paul Stoffels, scientific director of J&J.
The company added that it forwarded the new data to the Food and Drug Administration (FDA), as the US food and drug regulatory body is known. -market in New York.